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In the past several years, next-generation sequencing (NGS) 
technologies have greatly revolutionized our approaches to 
explore and depict the characteristics and functions of the 
genomes for various species. The NGS technologies have 
been broadly used in diverse fields including genomics 
(genome sequencing and exome sequencing) [1,2], tran-
scriptomics (RNA-Seq) [3,4] and epigenomics (ChIP-Seq, 
MeDIP-Seq, MBD-Seq, MRE-Seq and etc) [5–7], and a 
host of important findings have been achieved in these areas. 
Science China Life Sciences also has published a number of 
intriguing papers related to the NGS technologies in recent 
years [8–15]. Generally, if the studied organism does not 
have available reference genome, one can sequence its 
DNAs and then construct the genome using de novo assem-
bly. Furthermore, the genome and exome sequencing enable 
researchers to identify and characterize the SNPs (single 
nucleotide polymorphisms), indels (insertions and deletions), 
inversions and other structural variations of interested spe-
cies at single nucleotide resolution to investigate the under-
lying mechanisms of certain phenotypes or diseases. Using 
the whole transcriptome sequencing (RNA-Seq) technology, 
researchers have the opportunities to comprehensively in-
spect the transcriptional events and expression profiles of 
genes in cells [11,16]. Many applications have been carried 
out with RNA-Seq, such as exon-exon splice junction de-
tection, alternative splicing identification, gene and isoform 
expression quantification, gene fusion inference and etc. In 
particular, RNA-Seq allows for reconstructing the tran-
scriptome and identifying novel genes/isoforms of particular 
organism as well, which cannot conduct with microarrays. 
To study the epigenetic marks responded to environmental 
and developmental signals, NGS technologies can also be 
employed to profile the histone modifications (ChIP-Seq) 
and DNA methylations (MeDIP-Seq, MBD-Seq and 
MRE-Seq) in normal and disease states. Since NGS has the 
unsubstitutable advantages, many laboratories have adopted 
this technology for various researches. However, many bi-
ologists have not realized that the sequencing depth is di-
rectly associated with the number of detectable genes and 
SNPs, as well as other gene features, different experiments 
with different goals need to use distinct NGS strategies to 
generate related data. Xiao et al. [17] have summarized the 
applications with different depths, which provide a useful 
reference for biologists to design their related experiments. 
Meanwhile, the External RNA Control Consortium (ERCC) 
data has been proposed as internal control to monitor the 
consistence and reproducibility of different RNA-Seq data 
[18], Shi LeMing’s group [19] has evaluated the usages of 
ERCC between different experiments for single organism 
and between different organisms, they found that the gene 
expression measurement highly depends on the RNA en-
richment protocols (Poly(A) selection and RiboZero), which 
imply that the integration of multiple gene expression data 
from different RNA-Seq protocols should take cautions. 
The internal control is very important for monitoring the 
consistence between different NGS experiments, especially 
for the investigation of single cell expression profile. Oth-
erwise, the technical artifacts and truly biological variations 
between different single cells will not be distinguished.   
Personalized medicine refers to the right drug for the 
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right person at the right time with right dose. The first step 
for realizing personalized medicine is to decipher the dis-
ease related and drug sensitive genes and SNPs at mul-
ti-levels, and then carry out massive genetic screening for 
identifying those variations on each individual genome. For 
this purpose, NGS has enormously accelerated the advance 
of personalized medicine [20,21] and has been utilized to 
identify those variations of human genome and epigenome, 
including those variations for diseases. Together with other 
experimental analyses, it enables researchers to further un-
cover the causative mechanisms of genotype to phenotype. 
Through the exploration on the relevant NGS data and other 
related data, biomarkers for diagnosis, prognosis and thera-
py are being explored for different diseases. The related 
new findings will substantially improve patient treatments 
and facilitate drug developments. However, different indi-
viduals may have distinct response to the same drug owing 
to the variations among their genomes and/or epigenome. 
To ensure the drug safety and efficacy, it is necessary to 
screen the genetic variations for each individual. The ad-
vance in NGS technology makes it become faster, cheaper 
and more accurate approach for us to obtain a panoramic 
view of the variations among individuals; it also promises to 
accurately diagnosis and track the patients’ response to 
drugs in therapy, and help to optimize the drug usage to 
reduce the medication side effect. In this special issue, sev-
eral papers have touched this topic and discussed the appli-
cation of NGS on disease studies. Chen’s group discuss the 
ocular gene therapies and the identification of the related 
causative genes for molecular diagnosis with NGS for reti-
nal disorders [22]; Ning and his colleagues [23] summarize 
the progress of Abacavir-induced hypersensitivity reaction 
study and discuss the potential application of NGS in trans-
lational pharmacogenetics field for personalized medicine. 
Although the NGS technologies benefit a variety of 
studies, many challenges remain to be resolved to accurate-
ly and effectively process and interpret the NGS data. The 
challenges of analyzing NGS data come from the limitations 
of both NGS technologies and the correlated bioinformatics 
software. One of the challenges is the sequencing accuracy. 
Although NGS technologies can generate significant 
amount of data compared with Sanger’s method, their se-
quencing accuracy is lower by 2–3 orders of magnitude than 
the latter one. Also each NGS platform currently on market 
has its own inherent biases with special error patterns which 
have great impacts on the data interpretations, such as SNP 
identification, SNV and indel detection. For this reason, we 
believe that many reported SNPs identified by the NGS 
technologies are false results and need to be further verified. 
To evaluate the effects and the quality of NGS technologies 
and the analytic bioinformatics pipelines for realizing per-
sonalized medicine, FDA (U.S. Food and Drug Administra-
tion, http://www.fda.gov/) initiated the SEQC (Sequencing 
Quality Control) project to assess the technical performance 
of different NGS technologies and the advantages and limi-
tations of diverse bioinformatics strategies. Meanwhile, to 
facilitate the innovation and reduce the cost of the NGS 
technologies, NIH also launched the challenge grants for the 
technology development several years ago, with the hope 
that the cost of whole genome sequencing will be under 
1000 USD in the near future [24]. Ultimately the low cost 
will allow sequencing the genome of an individual as a rou-
tine medical test and making the personalized medicine 
come true in reality. 
Compared with Sanger sequencing method, NGS vastly 
increases the output with significant cost and time effec-
tiveness for sequencing, however, the reads of NGS are 
largely shorter than the ones from original Sanger methods 
in length with relatively higher sequencing errors in the 
reads. Furthermore, the huge amount of NGS data greatly 
raise the sequencing coverage, but more computational re-
sources and more effective bioinformatics algorithms are 
needed to smoothly process the colossal dataset. In addition, 
the short length of NGS reads poses the challenge for 
short-read mapping and de novo assembly. Because the eu-
karyotic genomes (especially for mammals) usually contain 
many repetitive and homologous regions, these elements 
may result in the alignment ambiguities and assembly col-
lapse. The sequencing errors of NGS further aggravate the 
difficulties for precisely conducing short-read alignment, de 
novo assembly, SNP calling, RNA-editing identification, 
gene fusion detection and other NGS applications. To alle-
viate the severity of these NGS problems, corresponding 
analytical algorithms are undergoing fast revolution and an 
increasing number of related software are emerging to ad-
dress these challenges. In this issue, Hong and his col-
leagues have critically reviewed the related bioinformatic 
tools in each step of NGS data generation and processing 
[25]. Powerful bioinformatics tools can solve a portion of 
NGS problems to some extent, but the improvements of 
sequencing technologies are the fundamental way to thor-
oughly conquer the NGS limitations.  
To conduct the NGS data analyses, lots of bioinformatics 
algorithms have been developed for diverse applications. 
Short-read alignment and assembly are two basic analyzing 
approaches, and they are crucial for reference-based and 
reference-independent studies, respectively [11,12]. In gen-
eral, when the reference genome is available, the first step is 
to implement short-read mapping; otherwise, de novo as-
sembly of short reads may need to be carried out instead. 
Before conducting any type of NGS data analysis, it is im-
portant to check the sequencing quality of data and remove 
those low quality reads or bases if necessary. Only with the 
high quality of the sequencing data, can we correctly ana-
lyze them and obtain accurate results. For each kind of NGS 
applications in genomics, transcriptomics and epigenomics, 
a number of relevant tools may be available to accomplish 
the associated analysis. Meanwhile, each one of the soft-
ware often has multiple parameters that can be set by users 
based on their requirements. Each software has its own 
strengths and weaknesses, moreover, distinct parameter 
settings of the same tool may also result in different results. 
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Therefore, it is necessary to test the performance and pa-
rameters of corresponding tools before employing appropri-
ate software on the basis of sequencing data properties. To 
this end, two papers in this issue have evaluated the perfor-
mance of different bioinformatics tools for transcriptome 
reconstruction with RNA-Seq data [26,27]. On the other 
hand, multiple analyzing steps are normally needed to reach 
the research goals, and the tools from each step are usually 
needed to combine to finish all the involved analyses. Thus, 
choosing an optimal combination of bioinformatics software 
is high recommended to fulfill the aims of the study as well.  
The NGS technologies are in continuous revolution along 
with the improvements of correlated bioinformatics algo-
rithms. Many aspects of NGS technologies will be signifi-
cantly improved in the future, including the short read 
length, sequencing depth, relatively higher sequencing er-
rors, the sequencing cost and time [28]. Those progresses 
will vastly facilitate the applications of NGS technologies in 
personalized medicine field. New powerful bioinformatics 
tools will also be designed to meet the changes of NGS 
technologies and effectively handle the NGS data with 
higher accuracy. It is worth noting that the human reference 
genome and related gene annotations are crucial for the ap-
plication of personalized medicine, however, it is still in-
complete [29]. With the advances in both sequencing tech-
nologies and computational algorithms, the reference ge-
nome will be further refined and those unidentified 
genes/isoforms will be eventually annotated. Collectively, 
the NGS technologies and relevant bioinformatics tools 
provide us important approaches to explore masses of bio-
logical issues related to human diseases and drug sensitivi-
ties and illustrate their underlying mechanisms, but we need 
to carefully process and interpret the NGS data in consider-
ation of the limitations from both technologies and algo-
rithms. We believe the evolutions of sequencing technolo-
gies and analyzing tools will consistently boost the devel-
opments and realization of personalized medicine and bene-
fit the health of human beings, the future of the NGS tech-
nologies on personalized medicine looks very promising but 
with great challenges.  
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